DDInter1266 DDInter1925
Naproxen is classified as a nonsteroidal anti-inflammatory dug (NSAID) and was initially approved for prescription use in 1976 and then for over-the-counter (OTC) use in 1994. It can effectively manage acute pain as well as pain related to rheumatic diseases, and has a well studied adverse effect profile. Given its overall tolerability and effectiveness, naproxen can be considered a first line treatment for a variety of clinical situations requiring analgesia. Naproxen is available in both immediate and delayed release formulations, in combination with sumatriptan to treat migraines, and in combination with esomeprazole to lower the risk of developing gastric ulcers.
Vemurafenib is a competitive kinase inhibitor with activity against BRAF kinase with mutations like V600E. It exerts its function by binding to the ATP-binding domain of the mutant BRAF. Vemurafenib was co-developed by Roche and Plexxikon and it obtained its FDA approval on August 17, 2011, under the company Hoffmann La Roche. After approval, Roche in collaboration with Genentech launched a broad development program.
Naproxen {u} (Compound) binds {v} (Gene) ALB
ALB {u} (Gene) is bound by {v} (Compound) Vemurafenib
Naproxen {u} (Compound) upregulates {v} (Gene) FAM63A
FAM63A {u} (Gene) is upregulated by {v} (Compound) Vemurafenib
Naproxen {u} (Compound) downregulates {v} (Gene) HAT1
HAT1 {u} (Gene) is downregulated by {v} (Compound) Vemurafenib
Naproxen {u} (Compound) causes {v} (Side Effect) Eosinophilia
Eosinophilia {u} (Side Effect) is caused by {v} (Compound) Vemurafenib
Naproxen {u} (Compound) binds {v} (Gene) ALB
ALB {u} (Gene) is associated with {v} (Disease) melanoma
melanoma {u} (Disease) is treated by {v} (Compound) Vemurafenib
Naproxen {u} (Compound) binds {v} (Gene) CYP1A2
CYP1A2 {u} (Gene) is bound by {v} (Compound) Etoricoxib
Etoricoxib {u} (Compound) resembles {v} (Compound) Vemurafenib
Naproxen {u} (Compound) upregulates {v} (Gene) FAM63A
FAM63A {u} (Gene) is regulated by {v} (Gene) ABCG2
ABCG2 {u} (Gene) is bound by {v} (Compound) Vemurafenib
Naproxen {u} (Compound) downregulates {v} (Gene) HAT1
HAT1 {u} (Gene) is regulated by {v} (Gene) PAN2
PAN2 {u} (Gene) is upregulated by {v} (Compound) Vemurafenib
Naproxen {u} (Compound) downregulates {v} (Gene) TXNDC9
TXNDC9 {u} (Gene) is regulated by {v} (Gene) BRAF
BRAF {u} (Gene) is bound by {v} (Compound) Vemurafenib
Naproxen {u} (Compound) causes {v} (Side Effect) Eosinophilia
Eosinophilia {u} (Side Effect) is caused by {v} (Compound) Donepezil
Donepezil {u} may cause a minor interaction that can limit clinical effects when taken with {v} Vemurafenib
Naproxen (Compound) binds ALB (Gene) and ALB (Gene) is bound by Vemurafenib (Compound)
Naproxen (Compound) upregulates FAM63A (Gene) and FAM63A (Gene) is upregulated by Vemurafenib (Compound)
Naproxen (Compound) downregulates HAT1 (Gene) and HAT1 (Gene) is downregulated by Vemurafenib (Compound)
Naproxen (Compound) causes Eosinophilia (Side Effect) and Eosinophilia (Side Effect) is caused by Vemurafenib (Compound)
Naproxen (Compound) binds ALB (Gene) and ALB (Gene) is associated with melanoma (Disease) and melanoma (Disease) is treated by Vemurafenib (Compound)
Naproxen (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Etoricoxib (Compound) and Etoricoxib (Compound) resembles Vemurafenib (Compound)
Naproxen (Compound) upregulates FAM63A (Gene) and FAM63A (Gene) is regulated by ABCG2 (Gene) and ABCG2 (Gene) is bound by Vemurafenib (Compound)
Naproxen (Compound) downregulates HAT1 (Gene) and HAT1 (Gene) is regulated by PAN2 (Gene) and PAN2 (Gene) is upregulated by Vemurafenib (Compound)
Naproxen (Compound) downregulates TXNDC9 (Gene) and TXNDC9 (Gene) is regulated by BRAF (Gene) and BRAF (Gene) is bound by Vemurafenib (Compound)
Naproxen (Compound) causes Eosinophilia (Side Effect) and Eosinophilia (Side Effect) is caused by Donepezil (Compound) and Donepezil may cause a minor interaction that can limit clinical effects when taken with Vemurafenib